Clinical trials for Chronic myeloid leukemia
46 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 2NCT07354074Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPNovartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- RECRUITINGNCT07375355Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in ChinaNovartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- ENROLLING BY INVITATIONNCT07383298Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated PhaseQian Jiang · PI: Qian Jiang, Dr.
- RECRUITINGPhase 2NCT06817720Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseM.D. Anderson Cancer Center · PI: Fadi Haddad, MD
- RECRUITINGNCT07061145A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid LeukemiaAzienda USL Reggio Emilia - IRCCS · PI: Isabella Capodanno, MD
- RECRUITINGPhase 2NCT06409936PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLGruppo Italiano Malattie EMatologiche dell'Adulto · PI: Fausto Castagnetti
- RECRUITINGPhase 2NCT06514534Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.Novartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- RECRUITINGPhase 1NCT06787144ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese ParticipantsEnliven Therapeutics · PI: Helen Collins, MD
- RECRUITINGNCT06297161A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).Pfizer · PI: Pfizer CT.gov Call Center
- ACTIVE NOT RECRUITINGPhase 1NCT06645886A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic MalignanciesKumquat Biosciences Inc.
- RECRUITINGNCT06665412Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CMLIl-Yang Pharm. Co., Ltd. · PI: Na Yun Kim
- RECRUITINGPhase 1NCT06401603A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid LeukemiaM.D. Anderson Cancer Center · PI: Nicholas Short, MD
- RECRUITINGPhase 1NCT06088888TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous LeukemiaShenzhen TargetRx Co., Ltd. · PI: Elias Jabbour
- RECRUITINGPhase 3NCT06423911Study of Olverembatinib (HQP1351) in Patients With CP-CMLAscentage Pharma Group Inc.
- RECRUITINGPhase 2NCT06236724Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.M.D. Anderson Cancer Center · PI: Elias Jabbour, MD
- ACTIVE NOT RECRUITINGPhase 3NCT05753384Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune SystemPoitiers University Hospital
- ACTIVE NOT RECRUITINGNCT04167683Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell TransplantRigshospitalet, Denmark · PI: Jan Christensen, post doc
- RECRUITINGNCT06119269Ponatinib in Chronic Myeloid Leukemia Patients in Chronic PhaseUniversity of Pisa · PI: Sara Galimberti, PhD
- RECRUITINGNCT05943522Asciminib RMP StudyNovartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPhase 3NCT05456191A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)Novartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- RECRUITINGPhase 4NCT04877522Asciminib Roll-over StudyNovartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- RECRUITINGNCT05439889Follow-up Study on Chronic Myeloid Leukemia Patients Achieving Treatment-free RemissionNational Taiwan University Hospital
- RECRUITINGPhase 1NCT05304377A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid LeukemiaEnliven Therapeutics
- RECRUITINGPhase 1NCT05367700A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.Jiangsu Hansoh Pharmaceutical Co., Ltd. · PI: Yu Hu
- RECRUITINGPhase 2NCT04838041Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationMedical College of Wisconsin · PI: Ehab Atallah, MD
- RECRUITINGPHASE1, PHASE2NCT04588922Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AMLSellas Life Sciences Group · PI: Dragan Cicic, MD
- RECRUITINGPHASE1, PHASE2NCT04835584KRT-232 and TKI Study in Chronic Myeloid LeukemiaKartos Therapeutics, Inc.
- ACTIVE NOT RECRUITINGNCT04645706Innate T Cells and TKI DiscontinuationPoitiers University Hospital · PI: Emilie CAYSSIALS
- ACTIVE NOT RECRUITINGPhase 1NCT05434312TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) PatientsShenzhen TargetRx Co., Ltd. · PI: Qian Jiang, MD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04258943Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid LeukemiaChildren's Oncology Group
- ACTIVE NOT RECRUITINGPhase 2NCT04147533Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid LeukemiaMasaryk University · PI: Daniela Zackova
- ACTIVE NOT RECRUITINGPhase 2NCT03610971Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase InhibitorsH. Lee Moffitt Cancer Center and Research Institute · PI: Javier Pinilla-Ibarz, MD, PhD
- ACTIVE NOT RECRUITINGPhase 2NCT04070443Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic PhaseCentre Leon Berard · PI: Franck-Emmanuel NICOLINI, MD
- ACTIVE NOT RECRUITINGPhase 3NCT03844048An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialAbbVie · PI: ABBVIE INC.
- ACTIVE NOT RECRUITINGPhase 2NCT03906292Frontline Asciminib Combination in Chronic Phase CMLUniversity of Jena · PI: Thomas Ernst, Prof. Dr.
- ACTIVE NOT RECRUITINGPhase 3NCT03722420Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)Il-Yang Pharm. Co., Ltd. · PI: Jiang Qian
- RECRUITINGPhase 1NCT03326310Selumetinib and Azacitidine in High Risk Chronic Blood CancersUniversity of Chicago · PI: Olatoyosi Odenike, MD
- RECRUITINGPhase 3NCT03459534A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIsIl-Yang Pharm. Co., Ltd. · PI: Dong Wook Kim
- ACTIVE NOT RECRUITINGPhase 2NCT029177202nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patientsEuropean LeukemiaNet · PI: Susanne Geiselhart
- ACTIVE NOT RECRUITINGPhase 2NCT02689440Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous LeukemiaM.D. Anderson Cancer Center · PI: Elias Jabbour, MD
- RECRUITINGNCT05963061Chronic Myeloid Leukemia (CML) Real-Life DatabaseUniversity Hospital, Clermont-Ferrand · PI: Marc BERGER, MD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02061800CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell TransplantDiane George · PI: Diane George, MD
- RECRUITINGPhase 2NCT01746836Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or NilotinibM.D. Anderson Cancer Center · PI: Elias Jabbour, MD
- RECRUITINGNCT01281735International Chronic Myeloid Leukemia Pediatric StudyPoitiers University Hospital · PI: Frederic MILLOT, MD
- RECRUITINGNCT00816114Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical TrialM.D. Anderson Cancer Center · PI: Koji Sasaki, M.D.
- ACTIVE NOT RECRUITINGPhase 2NCT00070499Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous LeukemiaNational Cancer Institute (NCI) · PI: Brian J Druker